Announcing the new issue of Prime’s managed care report, featuring the latest trends and updates in medical and pharmacy benefits

March 26, 2024

Prime Therapeutics/Magellan Rx (Prime/MRx) today launched the spring edition of Magellan Rx Report featuring timely topics such as single-treatment gene therapies and value-based contracting to address the dynamic growth trend and cost of gene and cell therapies. The triannual Magellan Rx Report provides an in-depth analysis of trends associated with high-cost, innovative therapies and the latest updates to inform our clients’ coverage and benefit decisions. 

The Magellan Rx Report spring edition includes expert commentary on the following topics: 

  • Single-treatment gene therapies and proper management  
  • Myasthenia gravis treatment advances and associated payer impact 
  • Ophthalmic update on new treatment options and management strategies 
  • Tumor biomarkers in breast cancer – ESR1 testing and targeted therapies 
  • Product spotlight: Leqembi for Alzheimer’s disease 
  • Update on new FDA-approved biosimilars 
  • Pipeline drug list update 

Download a copy of the report to go deeper into these timely trends. 

Stay current on ways Prime/MRx is reimagining pharmacy management to provide the same care we would want for our loved ones. 

Related news


July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend


July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion


July 1, 2024

Prime Careers Spotlight: July 2024

Check out our latest job openings. Together, we can help make health care better by helping clients and members navigate pharmacy benefits.